Showing results (21-30 of 106) with videos related to

Sort By:
Pageof 11
ESMO Open|October 12, 2017
The care of adolescents and young adults with cancer: results of the ESMO/SIOPE surveyEmmanouil Saloustros, Daniel P Stark, Kyriaki Michailidou, et al.
Endocrine-Related Cancer|November 3, 2016
Prkar1a gene knockout in the pancreas leads to neuroendocrine tumorigenesisEmmanouil Saloustros, Paraskevi Salpea, Matthew Starost, et al.
Molecular and Cellular Endocrinology|August 8, 2016
Celecoxib treatment of fibrous dysplasia (FD) in a human FD cell line and FD-like lesions in mice with protein kinase A (PKA) defectsEmmanouil Saloustros, Sisi Liu, Edward L Mertz, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 27, 2015
Hematopoietic neoplasms in Prkar2a-deficient miceEmmanouil Saloustros, Paraskevi Salpea, Chen-Feng Qi, et al.
Endocrine-Related Cancer|October 7, 2015
Celecoxib reduces glucocorticoids in vitro and in a mouse model with adrenocortical hyperplasiaSisi Liu, Emmanouil Saloustros, Annabel Berthon, et al.
International Journal of Oncology|December 25, 2015
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)George Mihai Nitulescu, Denisa Margina, Petras Juzenas, et al.
Breast Cancer Research and Treatment|November 17, 2014
Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG)Emmanouil Saloustros, Nikolaos Malamos, Ioannis Boukovinas, et al.
Human Molecular Genetics|August 7, 2015
Haploinsufficiency for either one of the type-II regulatory subunits of protein kinase A improves the bone phenotype of Prkar1a+/- miceSisi Liu, Emmanouil Saloustros, Edward L Mertz, et al.
Cancer Immunology, Immunotherapy : CII|October 9, 2025
Profiling of circulating T-cells with prognostic and predictive value in early and advanced stage PDACAnastasia Xagara, Konstantina Vasilieva, Alexandros Kokkalis, et al.
British Journal of Cancer|June 23, 2017
Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research GroupDimitrios Mavroudis, Emmanouil Saloustros, Ioannis Boukovinas, et al.
Pageof 11